|
 The Basel-based company in a statement on Monday
said it plans to file for U.S. approval of Bexsero as early as the
second quarter of this year.
Bexsero is widely seen as crucial to Novartis' vaccines business,
which has struggled to catch market leaders GlaxoSmithKline, Sanofi
and Merck. The business was the only one of Novartis' five divisions
to report a full-year operating loss in 2013.
The vaccine already has approval in Europe, Canada and Australia and
has been administered at several universities in the United States
to stop outbreaks of meningitis across campuses.
(Reporting by Caroline Copley; editing by Christopher Cushing)
[© 2014 Thomson Reuters. All rights
reserved.] Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
